10.1038/s41467-023-40061-y - Dose escalation and expansion cohorts...

This document has been corrected

Dose escalation and expansion cohorts in patients with advanced breast cancer in a Phase I study of the CDK7-inhibitor samuraciclib

10.1038/s41467-023-40061-y

Published Online: 2023-07-24

Journal: Nature Communications•Publisher: Springer Science and Business Media LLC

Authors: Ashwani Bahl•Carlo Palmieri•Glen Clack•Janine Mansi•Jason Melear•Joyce O’Shaughnessy•Laura Kenny•Linnea I. Chap•Matthew G. Krebs•Patrick Ward•Paul Richards•Pavani Chalasani•R. C. Coombes•Richard D. Baird•Rinath Jeselsohn•Sacha Howell•Sagar Sardesai•Simak Ali•Simon R. Lord•Stuart McIntosh•Tobias Arkenau•William Gradishar•Zahi Mitri

This document has been corrected

Dose escalation and expansion cohorts in patients with advanced breast cancer in a Phase I study of the CDK7-inhibitor samuraciclib

10.1038/s41467-023-40061-y

Published Online: 2023-07-24

Journal: Nature Communications

NOW

2025-03-06•Correction

Author Correction: Dose escalation and expansion cohorts in patients with advanced breast cancer in a Phase I study of the CDK7-inhibitor samuraciclib

10.1038/s41467-025-57535-w